178 related articles for article (PubMed ID: 2033489)
1. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
[TBL] [Abstract][Full Text] [Related]
2. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
3. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
4. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
5. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
6. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
7. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
8. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
9. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
[TBL] [Abstract][Full Text] [Related]
10. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
O'Hara CJ; Corson JM; Pinkus GS; Stahel RA
Am J Pathol; 1990 Feb; 136(2):421-8. PubMed ID: 2305835
[TBL] [Abstract][Full Text] [Related]
11. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
al-Saffar N; Hasleton PS
Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
[TBL] [Abstract][Full Text] [Related]
12. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
Müller AM; Franke FE; Müller KM
Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
[TBL] [Abstract][Full Text] [Related]
13. Malignant mesothelioma: ultrastructural distinction from adenocarcinoma.
Warhol MJ; Hickey WF; Corson JM
Am J Surg Pathol; 1982 Jun; 6(4):307-14. PubMed ID: 6287872
[TBL] [Abstract][Full Text] [Related]
14. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
Wolanski KD; Whitaker D; Shilkin KB; Henderson DW
Cancer; 1998 Feb; 82(3):583-90. PubMed ID: 9452278
[TBL] [Abstract][Full Text] [Related]
15. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
16. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
Ordóñez NG
Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
[TBL] [Abstract][Full Text] [Related]
17. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
18. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
Cakir E; Demirag F; Aydin M; Unsal E
Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
[TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
Galateau-Salle F
Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582
[TBL] [Abstract][Full Text] [Related]
20. Stereological evaluation of malignant mesothelioma versus benign pleural hyperplasia.
Bogers J; Jacobs W; Segers K; Van Daele A; Weyler J; Van Marck E
Pathol Res Pract; 1996 Jan; 192(1):10-4. PubMed ID: 8685035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]